JPET Minireview – Revised Manuscript

Therapeutic Basis of Generic Substitution of Antiseizure Medications

Sarah Elmer and Doodipala Samba Reddy*

*Department of Neuroscience and Experimental Therapeutics, Texas A&M University Health Science
Center College of Medicine, Bryan, TX 77807 (S.R. and D.S.R.).*

RUNNING TITLE: *Generic substitution of antiseizure medications*

***Correspondence to:**

D. Samba Reddy, Ph.D., R.Ph., FAAPS, FAAAS, FAES

Professor & Chancellor EDGES Fellow

Department of Neuroscience and Experimental Therapeutics

Texas A&M University Health Science Center College of Medicine

8447 Riverside Pkwy, Bryan, TX 77807-3260, USA

Tel: 979-436-0324; E-mail: sambareddy@tamu.edu

Manuscript statistics:

Total text Pages: 28

Abstract words: 249

Introduction words: 432

Main text discussion words: 4475

References: 73

Tables: 5

Figures: 1

ABBREVIATIONS: AHRQ, Agency for Healthcare Research and Quality; ASM, antiseizure medication; AUC, area under the concentration time curve; CI, confidence interval; $C_{\max}$, peak plasma concentration; FDA, U.S. Food and Drug Administration; MEPS, Medical Expenditure Panel Survey; NTI, narrow therapeutic index; $t_{\max}$, time to reach peak plasma concentration; WSV, within-subject variability

Section Assignment: Neuropharmacology

ABSTRACT

More than thirty antiseizure medications (ASMs) are available for treating epilepsy. ASMs differ in their potency and efficacy in controlling seizures by acting on diverse targets in the brain, often with variable pharmacokinetics. Moreover, nearly 30% of people with epilepsy have drug-resistant or intractable seizures. Generic substitution of ASMs is a complex issue. It is thought that generic substitution in people with epilepsy may cause problems because FDA rules allow too much variability across products. The standard bioequivalence range (80% to 125%) appears too broad for many ASMs, especially those exhibiting little separation between therapeutic and toxic levels. Hence, sub-therapeutic concentration may lead to therapeutic failure with seizure recurrence, which could be life threatening. A supra-therapeutic level could result in adverse effects or compliance issues. There are reported issues with generic substitutions of phenytoin, topiramate, levetiracetam, carbamazepine, and lamotrigine. There is discussion in the epilepsy community about additional guidelines, including designation of generic ASMs as Narrow Therapeutic Index (NTI) drugs and how patient education plays a role in generic substitution. Overall, based on the published evidence on specific generic ASMs, FDA bioequivalence standards are not the cause of problems with generic ASM substitution. Rather, it is imperative that physicians and pharmacists provide adequate patient education on what to expect when switching to generic ASMs, including changes in medication shape, color and consequences. Another suggestion would be to consider that all ASMs be considered for inclusion in NTI class to prevent the clinical outcome issues associated with generic ASM switching.

SIGNIFICANCE STATEMENT – *There are critical aspects to consider when switching from a brand name antiseizure medication (ASM) when a generic becomes available or switching between generics. Generic ASMs are interchanged with little consideration of differences in therapeutic equivalence and other clinical factors. This article describes key issues on generic substitution of ASMs and highlights critical pharmacotherapeutic issues associated with generic ASMs including adverse clinical consequences. Many therapeutic issues can be mitigated if all ASMs are categorized as NTI drugs.*

Introduction

Epilepsy is a chronic neurological condition characterized by repeated unprovoked seizures and a spectrum of neuropathology. It is estimated that the worldwide prevalence of individuals with active epilepsy is around 0.5% to 1%, corresponding to about 65 million people (Kros et al., 2015; Sander, 2003). Currently, there are no pharmacological therapies that offer a cure for epilepsy (Reddy and Golub, 2016). Antiseizure medications (ASMs) offer adequate seizure control for many patients, allowing them to lead a normal life (Kwan and Sander, 2004). In fact, up to 70% of patients taking ASMs can be seizure-free with the appropriate dose and type of ASM (Heaney and Sander, 2007). Pharmacological treatments vary depending on the type of epilepsy. Epileptic seizures that arise focally in a cortical site are referred to as focal seizures and comprise 60% of all seizures (Duncan et al., 2006; Goldenberg, 2010; Kammerman and Wasserman, 2001). The other 40% of epileptic seizures involve arise from both cerebral hemispheres and are known as generalized seizures (Duncan et al., 2006; Goldenberg, 2010; Kammerman and Wasserman, 2001).

The different types of epilepsy and variety in epileptic seizures that present in patients has resulted in a demand for the creation of multiple ASMs. The goals of ASM therapy are to completely eliminate or reduce seizures as much as possible, avoid adverse side effects from medication, and to help patients return to normal activities and maintain a normal lifestyle (Goldenberg, 2010). ASMs can be separated into two general categories: broad-spectrum and narrow-spectrum medications. As the name implies, broad-spectrum ASMs treat multiple types of epilepsy, while narrow-spectrum ASMs are used primarily for the treatment of focal seizures (Reddy, 2020). Some of the most common generic ASMs available in the U.S. are listed in Table 1, with the brand drug name in parentheses (Brodie et al., 2016; Lewis, 1978; Reddy, 2020). The classification of different ASMs into broad-spectrum and narrow-spectrum has some relation to the mechanism of action of each drug. The molecular classification of these drugs can be seen in Table 2 (Reddy, 2020).

There are many bioequivalence and therapeutic issues to consider when switching from a brand name ASM when a generic becomes available or switching between generics from different manufacturers. Although frequent generic substitution of ASMs in people with epilepsy can cause clinical problems because FDA rules allow too much variability across products, such variability is a critical point for discussion among other issues with generic ASMs. This article describes the key differences between generic and brand-name ASMs, highlights critical pharmacotherapeutic issues associated with generic ASMs, and examines specific studies on generic substitutions of certain ASMs.

Substitution of Generic ASMs

Rationale for Prescribing Generic ASMs

The U.S. Food and Drug Administration (FDA) defines a generic drug as a medication that is identical—or bioequivalent—to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use (Alfonso-Cristancho et al., 2015).

Over the years, physicians have gradually shifted from prescribing brand-name drugs to generic medications because of low cost to patients. Many health insurance plans operate under a tiered system for prescription medications. These plans often rely on a formula that accounts for how much the medication will cost the insurance company compared to the cost of the same generic drug. More expensive medications fall into a tier that increases cost to patients, while generic medications and other substitutes fall into a different tier that is more affordable to patients. These plans generally serve as an incentive for beneficiaries to choose generic medications to save money. Additionally, they simultaneously encourage pharmaceutical manufacturers to lower the cost of drugs, with the understanding that the medication will be placed into a more affordable tier level (Goldman et al., 2007).

The cost of a generic drug is generally 20% to 90% less expensive than the brand-name equivalent. Furthermore, in 2010, the use of FDA-approved generic medications saved a total of \$158 billion, amounting to savings of \$3 billion a week (Dunne et al., 2013). These savings have a sizable impact on adherence to drug therapy, because patients can afford to purchase medication (Goldman et al., 2007; Kesselheim et al., 2006; Shrank et al., 2006). The financial impact of generic ASMs plays an even more important role for economically disadvantaged patients or those without health insurance (Atif et al., 2016).

Prescribing Trends of ASMs

More than thirty ASMs are available for treating epilepsy, including many new drugs approved within the past two decades. A timeline of the introduction of first, second, and third generations of ASMs is depicted in figure 1 (Löscher and Klein, 2020). The top 10 generic ASMs prescribed in the U.S. were determined using data from the Medical Expenditure Panel Survey (MEPS) gathered by the Agency for Healthcare Research and Quality (AHRQ). This data, collected and organized by ClinCalc.com into a Drug Stats database, provides information about the top 200 most commonly prescribed drugs of 2018. This data was used as the basis for the article “Comprehension of Top 200 Prescribed Drugs in the US.” Of the top 200 drugs, generic ASMs comprise 11 of these. Gabapentin topped the list as the 11th most

commonly prescribed medication in the U.S. A brief overview of this data, including ranking and total number of prescriptions for each drug, is summarized in Table 3.

Generic Drug Approval Process and Therapeutic Problems

Bioequivalence

To receive approval from the FDA, generic drug manufacturers must undergo a rigorous process to demonstrate that the generic version is bioequivalent to the brand-name. Bioequivalence is defined by the FDA as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study (Chen et al., 2001). To determine bioequivalence, it is critical to first examine bioavailability. Bioavailability is defined by the FDA as the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action (Chen et al., 2001). In determining the bioavailability of a drug, three pharmacokinetic factors must be considered: peak plasma concentration ($C_{\max}$), the time to reach peak plasma concentration ($t_{\max}$), and area under the concentration time curve (AUC). The $C_{\max}$ and AUC are important in determining bioequivalence, as the $C_{\max}$ represents the maximum concentration of a drug in the blood plasma at a given time ($t_{\max}$), while the AUC represents the total concentration of the drug that is absorbed.¹⁸ Current FDA regulations state that a generic medication can meet bioequivalence standards, given that the AUC and $C_{\max}$ ratios of both the generic and brand-name drug fall within a range of 80% to 125% with a 90% confidence interval (CI) (Atif et al., 2016; Berg et al., 2017; Chow, 2014; Rani and Pargal, 2004).

Bioequivalence and its relation to therapeutic equivalence are further complicated by differences in metabolism between various ASMs. Many ASMs are metabolized by the hepatic microsomal system, meaning that certain drugs can induce this system, thereby diminishing the effects of a given ASM. Alternatively, some drugs may inhibit this system, resulting in the enhancement and supratherapeutic concentrations of ASMs. This can result in significant drug interactions, especially in patients taking multiple medications. The enzyme properties of different ASMs are summarized in Table 4 (Reddy, 2020).

Narrow Therapeutic Index

In considering the synthesis of bioequivalent generic ASMs, it is important to consider those with a narrow therapeutic index (NTI). According to the FDA, drugs are classified as NTI if the difference in ratio between the median minimum toxic concentration and the minimum effective blood concentration is

less than two-fold (Shaw and Hartman, 2010; Tamargo et al., 2015). Knowledge of NTI ASMs is especially important when considering therapies for epilepsy. Specifically, clinicians should pay close attention to the therapeutic window of a drug, which reflects the concentration range that provides therapeutic benefit without causing toxicity (Blix et al., 2010). NTI drugs have a very narrow therapeutic window. A narrow therapeutic window means that a small difference in dosing or blood concentration of the medication can have potentially life-threatening toxic effects (Tamargo et al., 2015). As a result, the doses of these drugs must be monitored closely and administered carefully to prevent toxicity in patients (Blix et al., 2010; Tamargo et al., 2015).

Five ASMs are commonly listed as NTIs: carbamazepine, phenytoin, phenobarbital, ethosuximide, and valproic acid (Atif et al., 2016; Greenberg et al., 2016; Hottinger and Liang, 2012; Jankovic and Ignjatovic Ristic, 2015; Sankar and Glauser, 2010). In regard to epilepsy therapy, there are potential problems associated with the substitution of brand-name ASMs with generics. Using the classic 80% to 125% range approved by the FDA for generic medications poses a threat to individuals who have a high sensitivity to plasma ASM concentration. Generic ASMs that fall below this range can be therapeutically ineffective, resulting in a greater occurrence of seizures and other complications from epilepsy. Conversely, generic ASMs that exceed the upper limit can cause serious adverse effects or toxicity in patients. Table 5 lists the therapeutic range and the FDA bioequivalence extrapolated therapeutic range for seven ASMs, including the five that are classified as NTI (Atif et al., 2016; Fuentes et al., 2018).

Potential Problems with FDA Therapeutic Ranges

The literature shows that there have been health concerns associated with the use of generic ASMs over their brand-name equivalent. There are multiple reports from clinicians that FDA criteria for generic ASMs pose a risk to patients because of the difference between bioequivalence and therapeutic equivalence. Specifically, the AUC and $C_{\max}$ of generic ASMs are only required to be within a range of 80% to 125%. However, at a $C_{\max}$ of 81% of the normal therapeutic range, doses that are too low may result in breakthrough seizures and failure of ASM therapy, resulting in an increase in the frequency of seizures (Atif et al., 2016; Berg, Gross, Tomaszewski, et al., 2008; Hartley et al., 1990, 1991; Jain, 1993; Koch and Allen, 1987; Meyer et al., 1992; Sachdeo and Belendiuk, 1987; Welty et al., 1992). In fact, two-thirds of physicians report that they have treated a patient who experienced a breakthrough seizure after switching from a brand-name ASM to a generic (Berg, Gross, Haskins, et al., 2008; Berg, Gross, Tomaszewski, et al., 2008; Fitzgerald and Jacobson, 2011; Guberman and Corman, 2000; Wilner, 2004). This has resulted in motor vehicle accidents, missed time at work, and increased visits to hospitals and physicians (Berg, Gross, Tomaszewski, et al., 2008).

Conversely, at a $C_{\max}$ of 124% of the normal therapeutic range, doses that are too high may result in drug toxicity, increased drug serum levels, undesired drug interactions, and other adverse side effects (Atif et al., 2016; Borgheini, 2003; Chaluvadi et al., 2011; Chen et al., 1982; Levine et al., 2000; Soryal and Richens, 1992).

Because of these reported problems with the FDA therapeutic ranges, drugs classified as NTI are subject to stricter regulations for substitution of brand-name with generic counterparts in some states. In 2008, Berg, et al. published a paper that incorporated the 2006 state formulary guidelines by the National Association of Boards of Pharmacy. The formulary guidelines outlined the specific NTI drug substitution laws for each of the 50 states, Washington D.C., Guam, and Puerto Rico. Of these, 13 of the 43 states had a designated list of drugs that are not substitutable (NTI). Even in states that did not have a designated list of NTI drugs, there are regulations in place that allow prescribing physicians to prevent generic substitution of drugs (Berg, Gross, Tomaszewski, et al., 2008).

Reported Bioequivalence and Clinical Problems with Generic ASMs

Phenytoin

There are five major studies published on the problems associated with administration of generic phenytoin vs. its brand-name counterpart. The study by Shin et al. took a retrospective approach using electronic medical records and determined that the bioavailability of phenytoin was significantly different between generics (Shin et al., 2014). Soryal and Richens looked at the bioavailability of brand-name and generic versions of phenytoin and determined that substitution between generic phenytoin or between generic phenytoin and brand-name Epanutin caused a change in bioavailability, which was likely to have an adverse effect on seizure control and increase the incidence of side effects (Soryal and Richens, 1992). A review conducted by Borgheini examined literature about bioequivalence and therapeutic efficacy of different ASMs. In this, literature by Rosenbaum et al. showed that plasma levels of phenytoin were 31% lower after switching from brand-name to generic phenytoin (Borgheini, 2003; Rosenbaum et al., 1994). Yamada and Welty did a systematic review of prospective and retrospective studies on generic substitution of ASMs, while Chen examined the bioavailability of phenytoin from different generic formulas. These two studies both determined that the serum concentrations differed between generic and brand-name phenytoin. These studies illustrate unfavorable outcomes with generic phenytoin products (Atif et al., 2016; Borgheini, 2003; Chen et al., 1982; Rosenbaum et al., 1994; Shin et al., 2014; Soryal and Richens, 1992; Yamada and Welty, 2011).

Topiramate

In Duh et al., medical and pharmacy claims from patients on topiramate were gathered and observation periods were sorted into 3 categories: brand use, single-generic use, and multiple-generic use. The study found that there was a significant association between multiple-generic substitution of topiramate and adverse health outcomes, including hospitalizations and injuries, as well as increased costs for treatment. This indicates that substitution between generic versions of topiramate poses a risk to patients (Atif et al., 2016; Duh et al., 2009).

Levetiracetam

In 2009, Armstrong et al. compared case studies on four different patients with brain tumors who had been switched from brand-name Keppra to generic levetiracetam. All four patients experienced breakthrough seizures after switching medication, despite no change in their brain tumor size or severity. This demonstrates that changing from brand-name to generic levetiracetam may not be suitable because the generic formulation may not be therapeutically equivalent (Armstrong et al., 2010). Fitzgerald and Jacobson also reported that four patients experienced an increase in breakthrough seizures after switching from Keppra to generic levetiracetam. After switching back to Keppra, all patients saw their seizure activity return to normal baseline (Fitzgerald and Jacobson, 2011). Chaluvadi and colleagues conducted a retrospective chart review of 260 patients who had switched from brand-name to generic levetiracetam. Of these patients, 42.9% switched back to the brand-name medication because of an increase in seizure frequency (19.6%) or an increase in adverse side effects (3.3%). These findings indicate that there are concerning outcomes associated with the substitution of brand-name with generic levetiracetam (Armstrong et al., 2010; Atif et al., 2016; Chaluvadi et al., 2011; Fitzgerald and Jacobson, 2011).

Carbamazepine

A review conducted by Borgheini examined literature about bioequivalence and therapeutic efficacy of different ASMs. In his review, Borgheini included a study which demonstrated that switching from brand-name to generic carbamazepine resulted in a recurrence of seizures (Borgheini, 2003). Desmarais et al. conducted a literature review of problems reported with switching from brand-name to generic psychotropic medications, which included carbamazepine. Many of the authors included in the literature review reported problems with increased seizures and lower drug levels in the body, without a change in dosage, after switching from brand-name to generic carbamazepine (Desmarais et al., 2011; Jain, 1993). Conversely, some authors cited toxicity issues. Specifically, a study by Vergely and team showed that one patient experienced a 3-fold increase in carbamazepine levels after switching from brand-

name to generic carbamazepine, which resulted in adrenal decompensation (Vergely et al., 2002). In 2008, Berg et al. reported on fifty patients who experienced a breakthrough seizure or increased seizure frequency after switching from a brand-name to a generic ASM. Of these 50 patients, 7 of them were taking carbamazepine. Additionally, in 26 of the cases, the blood ASM level was recorded before and after switching from brand-name to generic. Of these 26 patients, 21 of them experienced lower drug concentration levels at the time of their breakthrough seizure. In fact, the drug levels of patients taking generic carbamazepine decreased by 20%, on average. These findings show the concerns associated with substitution of generic for brand-name carbamazepine (Berg, Gross, Tomaszewski, et al., 2008; Borgheini, 2003; Desmarais et al., 2011; Jain, 1993; Vergely et al., 2002).

Lamotrigine

Desmarais et al. published a review of problems reported with switching from brand-name to generic psychotropic medications, which included lamotrigine (Desmarais et al., 2011). In this review, he included a publication from Makus and McCormick, which examined adverse reaction forms that had been submitted to the pharmacy by physicians whose patients had an adverse reaction to substitution with generic lamotrigine. Of these 14 patients, 11 reported loss of seizure control after being switched to the generic. However, when 10 of the patients were switched back to brand-name lamotrigine, 80% of them regained seizure control (Makus and McCormick, 2007). Similarly, in a report from Nielsen et al., nine patients received drug monitoring while switching between lamotrigine formulations. One patient's $C_{\max}$ increased by 21% after switching from brand-name to generic lamotrigine and he subsequently experienced ataxia and falls. Another patient's $C_{\max}$ decreased by 17% after switching from brand-name to generic lamotrigine and they experienced seizures, even though they had previously been seizure-free for a year and a half before switching. These findings show the complications associated with switching patients to generic lamotrigine (Desmarais et al., 2011; Makus and McCormick, 2007; Nielsen et al., 2008).

Clinical Considerations for Changing Between Generic ASMs

Though there are numerous reports by physicians of problems with switching between generic and brand-name ASMs, this is not standard for all patients. On average, the AUC of most generic medications differ from the brand-name by less than 10% of their expected value. (Davit et al., 2009) This indicates that the issue with substitution of ASMs does not solely lie with variability between brand-name and generic medications. With this in mind, it is important to note that bioequivalence between a generic and

brand-name medication does not necessarily equate to bioequivalence between different generics. This means that two different generic ASMs could separately meet FDA bioequivalence standards when compared to a brand-name medication. However, when compared to one another, they may not be bioequivalent to each other, resulting in clinically significant changes in plasma concentration of ASMs. Theoretically, given the FDA-accepted range of 80 to 125% for generic medications, if one generic was at the lowest possible acceptable end and the other at the highest, the difference between the AUC and C_{max} ratios between the two could amount to nearly 50%.

Studies by Karalis and colleagues showed that substitution between generic ASMs should not be considered therapeutically equivalent to switching between a generic and brand-name ASM (Atif et al., 2016; Karalis et al., 2013, 2014). In their 2013 study, they used Monte Carlo simulations of classic 2 x 2 bioequivalence studies to examine the effect of various factors on bioequivalence acceptance of generic ASM products. These factors include sample size, within-subject variability, and the true difference in pharmacokinetic values of the products being compared. Their findings showed that switches between bioequivalent generic ASMs could lead to larger changes in plasma levels and exposure than switching between brand and generics. Simply put, the simulation showed that two generic ASMs that are bioequivalent to the same original brand-name product may not be bioequivalent to one another (Karalis et al., 2013).

This argument is supported by Odi and team, who suggest that bioequivalence exists between brand-name and generic ASMs, but not between different generics. They assert that potential issues arise when switching is done between different generic ASMs. The potential risks of switching from one generic to another is lessened when products meet NTI criteria for bioequivalence and have little difference in their pharmacokinetic parameters (Odi et al., 2021).

In addition, women with pregnancy are considered a special population for therapeutic management. Pregnant women tend to have more breakthrough seizures than before conception. Pregnancy is associated with significant drop in plasma levels of ASMs that can have adverse clinical consequences (Pennell et al., 2022). According to this new study, ASMs such as lamotrigine, levetiracetam, zonisamide, lacosamide, and carbamazepine levels decreased by up to 56% in pregnancy as compared with post-partum values. A dosage adjustment of such ASMs and therapeutic drug monitoring are needed for optimal outcomes during pregnancy, including generic ASMs.

Studies Investigating Generic Substitution of ASMs

Position Statements

There are three major epilepsy organizations that have issued official position statements regarding the substitution of brand-name ASMs with generics. In 2007, the American Academy of Neurology (AAN) published a piece saying that they do not support the generic substitution of ASMs without prior approval from a patient's attending physician (Liow et al., 2007). After their position statement, they listed many other supporting opinions about generic ASM substitution. This list includes support for legislation that would mandate informed consent for both patients and physicians before any generic substitutions of ASMs are made (Liow et al., 2007).

Just a few months prior, the Epilepsy Foundation (EF) issued a statement in 2006 that closely mirrored the ideas expressed by the AAN. The EF stated that they are in strong support of informed consent for both physicians and patients before any type of ASM substitution is made. These substitutions include switching from brand to generic or even switching between generics. The EF also discouraged mandatory substitution of generic ASMs without authorization from the attending physician and patient (*Epilepsy Foundation Medication Switching Position Statement*, 2006).

The American Epilepsy Society (AES) issued a position statement in 2007 and then re-issued a new statement in 2016. The 2016 AES position statement was based off of results from two different bioequivalence studies funded by the FDA. These studies are the BioEquivalence in Epilepsy Patients (BEEP) and Equivalence Among Generic Antiepileptic Drugs (EQUIGEN) studies. AES stated that the experimental findings support the existing FDA standards for bioequivalence of generic ASMs. As a result, AES is in support of the FDA standards and asserts that there is no difference in bioequivalence between brand name and generic ASMs (Vossler et al., 2016).

BEEP Study

The BEEP Study was a randomized, double-blind, multiple-dose, steady-state, fully replicated study that compared generic lamotrigine to brand-name Lamictal (Ting et al., 2015). Specifically, the study examined pharmacokinetic performance in 35 “generic-brittle” patients already taking lamotrigine. “Generic-brittle” patients were those identified as potentially having problems switching from brand-name to generic medications because of (i) a history of exacerbation of seizures or side effects following ASM formulation changes; (ii) intolerable ASM side effects within the year prior to study; or (iii) refractory seizures within the last year prior to study, suggesting clinical sensitivity to higher peak plasma concentration of ASM or slightly lower drug exposure. Of the 35 patients who participated, 23 met two or more of the criteria (Ting et al., 2015).

In this four-period study, patients were repeatedly switched between generic and brand-name lamotrigine every 2 weeks. Patients were randomized to one of two sequences: generic, brand, generic,

and brand; or the reverse. Subsequent blood sampling was taken at the end of every 2 week period (Ting et al., 2015).

The results showed that neither the brand-name nor the generic showed identical pharmacokinetics in any of the patients when administered twice. Individual C_{max} and AUC ratios fell within $\pm 25\%$ and most C_{min} ratios also fell within this range. Overall, the findings showed that generic lamotrigine demonstrated bioequivalence to brand-name Lamictal in AUC, C_{max} , C_{min} and within-subject variability (WSV). In regard to seizure control, 32 of the 35 subjects reported that their seizure control was not worsened during the study. Similarly, no patients reported increased seizure severity. However, one subject experienced 267 short focal motor seizures without impairment of consciousness, which was a typical seizure type for this patient. However, the patient reported that this corresponded to “more than three times the number of seizures during the study” compared to their baseline. Most of these seizures occurred on generic lamotrigine, despite having very similar pharmacokinetic profiles during all four periods of the study. His seizures while taking generic lamotrigine did not correspond to lower plasma levels, as the profiles between generic and brand-name were nearly identical. When this subject is excluded, the total number of seizures between the generic and brand-name formulations is not substantially different. (Ting et al., 2015)

This suggests that current FDA bioequivalence standards are appropriate, given that the adverse events related to switching were not related to differences in pharmacokinetic profiles. However, this raises the issue that bioequivalence between brand-name and generics does not always equate to therapeutic equivalence.

EQUIGEN Study

The EQUIGEN study was randomized, double-blind, crossover study in patients already taking lamotrigine to examine generic-to-generic switches (Privitera et al., 2016). In the study, patients were allocated 1:1 to two treatment groups, with four study periods of 14 days each. At the end of each study period, patients were switched from one generic lamotrigine product to another. C_{max} and AUC were measured for each generic product in patients who completed the study. The findings showed that the 90% CI of the ratios of C_{max} and AUC fell within the FDA-approved range of 80% to 125%. This indicates bioequivalence between generic lamotrigine products. Of note, there were no significant changes in seizure frequency, loss of seizure control, or adverse events recorded during the study. Given that the different formulations of generic lamotrigine were shown to be bioequivalent with no difference in clinical outcomes, this suggests that the FDA requirements for bioequivalence are suitable (Privitera et al., 2016).

Conclusions and Perspectives

There are some reports that concludes that generic ASMs pose few issues as compared to branded versions (Holtkamp and Theodore, 2018; Kesselheim et al., 2010, 2013; Odi et al., 2021; Piñeyro-López et al., 2009; Privitera et al., 2016). In particular, Holtkamp and Theodore suggest that the high switchback rates for patients who switch to generic ASMs and then back to brand-name ASMs has more to do with improper administration of medication, rather than differing pharmacokinetics and pharmacodynamics between generic and brand-name ASMs. These authors suggest that changes in medication shape and color that result from a change in the drug manufacturer may confuse patients and result in nonadherence to generic ASMs. To avoid this complication, they suggest administering generics instead of brand-name ASMs when an ASM is first started, to prevent confusion among patients (Holtkamp and Theodore, 2018).

Similarly, Kesselheim and colleagues conducted a case control study that examined adherence to ASMs in the setting of changes in appearance and color. Specifically, the study looked at cases where patients became nonpersistent, defined as someone “failing to refill a prescription within 5 days of the elapsed days supplied.” Findings showed that changes in pill color specifically had a significant effect on the odds of nonadherence to ASMs (Kesselheim et al., 2013).

In the EQUIGEN study, Privitera and colleagues introduce the idea of the nocebo effect, defined as a situation where “an inert substance produces a perceived negative effect, or in this case, an equivalent substance produces a perceived less potent therapeutic effect or new adverse effect. Because patients and clinicians expect the generic products to be inferior, the therapeutic effect is assumed to be reduced.” Essentially, the concept of the nocebo effect is the opposite of the placebo effect. So, if a patient expects to have a negative experience after starting a new generic ASM, this results in the treatment having a more negative effect (Privitera et al., 2016).

However, there are a substantial number of reports and review articles by professional neurologists that indicate issues with generic ASMs, such as increased risk of seizures, inadequate seizure control and adherence issues. It is likely that there are lots of anecdotal or anonymous patient reports of seizures; many often not reported to the FDA or published in journals.

As such, prior to switching, physicians should have discussions with their patients to watch for breakthrough seizures or other adverse effects. Additionally, to help prevent the problems associated with generic ASM switching, providers must provide proper patient education on what to expect in order to increase adherence when switching between brand-name to generics or between generics. This includes

explaining differences in medication appearance so that patients know what to expect when they switch medications. This raises the question of how these providers can provide educational materials in a way that will be most beneficial to patients.

A study by Hohmann and team examined the opinions of patients and their caregivers regarding the use of FDA-developed educational materials as they pertain to generic drugs (Hohmann et al., 2019). Their findings identified a set of needs to increase receptiveness regarding educational material about generic drugs. Study participants identified all of the following as educational needs: (1) modernized graphics; (2) emphasis on generic cost-saving for consumers; (3) reduction of scare tactics when discussing adverse events; (4) dissemination of information directly from physicians and pharmacies (Hohmann et al., 2019)

Overall, based on the published evidence on specific generic ASMs, it is imperative that physicians and pharmacists provide proper patient education on what they can expect when switching from a brand-name to a generic or when switching between generics. Another suggestion would be to consider that all such ASMs be considered for inclusion in NTI class to prevent the adverse clinical outcome issues associated with generic ASM switching. ASM drug products with NTI designation will better serve the needs of epilepsy patients because they are better regulated for effective drug delivery with consistent clinical response.

AUTHORSHIP CONTRIBUTIONS

Wrote or contributed to the writing of the manuscript: Elmer and Reddy

REFERENCES

- Alfonso-Cristancho R, Andia I, Barbosa T, and Watanabe JH (2015) Definition and Classification of Generic Drugs Across the World. *Appl Health Econ Health Policy* **13** Suppl 1:S5-11.
- Armstrong TS, Choi S, Walker J, and Gilbert MR (2010) Seizure risk in brain tumor patients with conversion to generic levetiracetam. *J Neurooncol* **98**:137–141.
- Atif M, Azeem M, and Sarwar MR (2016). Potential problems and recommendations regarding substitution of generic antiepileptic drugs: A systematic review of literature. *SpringerPlus* **5**:182.
- Berg MJ, Gross RA, Haskins LS, Zingaro WM, and Tomaszewski KJ (2008) Generic substitution in the treatment of epilepsy: Patient and physician perceptions. *Epilepsy Behav* **13**:693–699.
- Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, and Haskins LS (2008) Generic substitution in the treatment of epilepsy: Case evidence of breakthrough seizures. *Neurology* **71**:525–530.
- Berg M, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ, Jiang W, Jiang X, Switzer RD, and Privitera MD (2017) Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. *JAMA Neurol* **74**:919–926.
- Blix HS, Viktil KK, Moger TA, and Reikvam A (2010) Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. *Pharm Pract (Granada)* **8**:50–55.
- Borgheini G (2003) The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. *Clin Ther* **25**:1578–1592.
- Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, Aldenkamp AP, and Steinhoff BJ (2016) Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review. *Pharmacol Rev* **68**:563–602.
- Chaluvadi S, Chiang S, Tran L, Goldsmith CE, and Friedman DE (2011) Clinical experience with generic levetiracetam in people with epilepsy. *Epilepsia* **52**:810–815.
- Chen ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D, Mehta M, Malinowski H, Lazor J, Huang SM, Hare D, Lesko L, Sporn D, and Williams R (2001) Bioavailability and bioequivalence: An FDA regulatory overview. *Pharm Res* **18**:1645–1650.
- Chen SS, Allen J, Oxley J, and Richens A (1982) Comparative bioavailability of phenytoin from generic formulations in the United Kingdom. *Epilepsia* **23**:149–152.

- Chow SC (2014) Bioavailability and Bioequivalence in Drug Development. *Wiley Interdiscip Rev Comput Stat* **6**:304–312.
- Davit BM, Nwakama PE, Buehler, GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, and Woodcock J. (2009) Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration. *Ann Pharmacother* **43**: 1583–1597.
- Desmarais JE, Beauclair L, and Margolese HC (2011) Switching from brand-name to generic psychotropic medications: A literature review. *CNS Neurosci Ther* **17**:750–760.
- Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MFT, and LeLorier J (2009) The risks and costs of multiple-generic substitution of topiramate. *Neurology* **72**:2122–2129.
- Duncan JS, Sander JW, Sisodiya SM, and Walker MC (2006) Adult epilepsy. *Lancet* **367**:1087–1100.
- Dunne S, Shannon B, Dunne C, and Cullen W (2013) A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. *BMC Pharmacol Toxicol* **14**:1.
- Epilepsy Foundation Medication Switching Position Statement*. (2006).
<https://www.epilepsy.com/sites/core/files/atoms/files/Medication%20Switching%20Position%20Statement.pdf>
- FDA Approved Drug Products, 2021*. (2021). :<https://www.accessdata.fda.gov/scripts/cder/daf/>
- Fitzgerald CL and Jacobson MP (2011) Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures. *Ann Pharmacother* **45**:e27.
- Fuentes AV, Pineda MD, and Venkata KCN (2018) Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice. *Pharmacy (Basel)* **6**:E43.
- Goldenberg MM (2010) Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment. *Pharm Ther* **35**:392–415.
- Goldman DP, Joyce GF, and Zheng Y (2007) Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. *JAMA* **298**:61–69.

- Greenberg RG, Melloni C, Wu H, Gonzalez D, Ku L, Hill KD, Hornik CP, Cohen-Wolkowicz M, and Guptill JT (2016) Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach. *Clin Neuropharmacol* **39**:232–240.
- Guberman A and Corman C (2000) Generic substitution for brand name antiepileptic drugs: A survey. *Can J Neurol Sci* **27**:37–43.
- Hartley R, Aleksandrowicz J, Bowmer CJ, Cawood A, and Forsythe WI (1991) Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy. *J Pharm Pharmacol* **43**:117–119.
- Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, and Forsythe WI (1990) Breakthrough seizures with generic carbamazepine: A consequence of poorer bioavailability? *Br J Clin Pract* **44**:270–273.
- Heaney DC and Sander JW (2007) Antiepileptic drugs: Generic versus branded treatments. *Lancet Neurol* **6**:465–468.
- Hohmann NS, Garza KB, Surry D, Hansen RA, Harris I, Kiptanui Z, Oguntimein O, Frost MM, and Qian J. (2019) Communicating benefits and risks of generic drugs to consumers: Patient and caregiver opinions of two FDA-developed educational materials. *Res Social Adm Pharm* **15**: 1489–1493.
- Holtkamp M and Theodore WH (2018) Generic antiepileptic drugs-Safe or harmful in patients with epilepsy? *Epilepsia* **59**:1273–1281.
- Hottinger M and Liang BA (2012) Deficiencies of the FDA in evaluating generic formulations: Addressing narrow therapeutic index drugs. *Am J Law Med* **38**:667–689.
- Jain KK (1993) Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example. *J R Soc Med* **86**:133–136.
- Jankovic SM and Ignjatovic Ristic D (2015) Is bioavailability altered in generic versus brand anticonvulsants? *Expert Opin Drug Metab Toxicol* **11**:329–332.
- Kammerman S and Wasserman L (2001) Seizure disorders: Part 1. Classification and diagnosis. *West J Med* **175**:99–103.
- Karalis V, Bialer M, and Macheras P (2013) Quantitative assessment of the switchability of generic products. *Eur J Pharm Sci* **50**:476–483.

- Karalis V, Macheras P, and Bialer M (2014) Generic products of antiepileptic drugs: A perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations. *CNS Drugs* **28**:69–77.
- Kesselheim AS, Fischer MA, and Avorn J (2006) Extensions of intellectual property rights and delayed adoption of generic drugs: Effects on medicaid spending. *Health Aff (Millwood)* **25**:1637–1647.
- Kesselheim AS, Misono AS, Shrank WH, Green JA, Doherty M, Avorn J, and Choudhry NK. (2013) Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence. *JAMA Intern Med* **173**: 202–208.
- Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, and Shrank WH (2010) Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: A systematic review and meta-analysis. *Drugs* **70**:605–621.
- Koch G and Allen JP (1987) Untoward effects of generic carbamazepine therapy. *Arch Neurol* **44**:578–579.
- Kros L, Eelkman Rooda OHJ, De Zeeuw CI, and Hoebeek FE (2015) Controlling Cerebellar Output to Treat Refractory Epilepsy. *Trends Neurosci* **38**:787–799.
- Kwan P and Sander JW (2004) The natural history of epilepsy: An epidemiological view. *J Neurol Neurosurg Psychiatry* **75**:1376–1381.
- Levine J, Chengappa KN, and Parepally H (2000) Side effect profile of enteric-coated divalproex sodium versus valproic acid. *J Clin Psychiatry* **61**:680–681.
- Lewis JR (1978) Valproic acid (Depakene). A new anticonvulsant agent. *JAMA* **240**:2190–2192.
- Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW, and American Academy of Neurology (2007) Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. *Neurology* **68**:1249–1250.
- Löscher W and Klein P (2020) The feast and famine: Epilepsy treatment and treatment gaps in early 21st century. *Neuropharmacology* **170**:108055.
- Makus KG and McCormick J (2007) Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. *Clin Ther* **29**:334–341.
- Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, and Shah VP (1992) The bioinequivalence of carbamazepine tablets with a history of clinical failures. *Pharm Res* **9**:1612–1616.

- Nielsen KA, Dahl M, Tømmerup E, and Wolf P (2008) Comparative daily profiles with different preparations of lamotrigine: A pilot investigation. *Epilepsy Behav* **13**:127–130.
- Odi R, Franco V, Perucca E, and Bialer M (2021) Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. *Epilepsia* **62**:285–302.
- Pennell PB, Karanam A, Meador KJ, Gerard E, Kalayjian L, Penovich P, Matthews A, McElrath TM, Birnbaum AK; MONEAD Study Group (2022). Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study. *JAMA Neurol.*, Feb **14**:e215487.
- Piñeyro-López A, Piñeyro-Garza E, Gómez-Silva M, Reyes-Araiza R, Flores-Diego MA, Borrego-Alvarado S, Gamino-Peña ME, Vargas-Zapata R, and Salazar-Leal ME (2009) Bioequivalence of single 100-mg doses of two oral formulations of topiramate: An open-label, randomized-sequence, two-period crossover study in healthy adult male Mexican volunteers. *Clin Ther* **31**:411–417.
- Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ, Jiang W, Jiang X, and Berg M. (2016) Generic-to-generic lamotrigine switches in people with epilepsy: The randomised controlled EQUIGEN trial. *Lancet Neurol* **15**: 365–372.
- Rani S and Pargal A (2004) Bioequivalence: An overview of statistical concepts. *Indian J Pharmacol* **36**:209–216.
- Reddy DS (2020) Clinical Pharmacology and Therapeutics of Antiepileptic Drugs for Treatment of Epilepsy and Seizure Disorders. *Int. J Pharm Sci Nanotechnology* **13**:5165–5180.
- Reddy DS and Golub VM (2016) The Pharmacological Basis of Cannabis Therapy for Epilepsy. *The J Pharmacol Exp Ther* **357**:45–55.
- Rosenbaum DH, Rowan AJ, Tuchman L, and French JA (1994) Comparative bioavailability of a generic phenytoin and Dilantin. *Epilepsia* **35**:656–660.
- Sachdeo RC and Belendiuk G (1987) Generic versus branded carbamazepine. *Lancet* **329**:1432.
- Sander JW (2003) The epidemiology of epilepsy revisited. *Curr Opin Neurol* **16**:165–170.
- Sankar R and Glauser TA (2010) Understanding therapeutic equivalence in epilepsy. *CNS Spectr* **15**:112–123.

- Shaw SJ and Hartman AL (2010) The Controversy over Generic Antiepileptic Drugs. *J Pediatr Pharmacol Ther* **15**:81–93.
- Shin JW, Chu K, Jung KH, Lee ST, Moon J, and Lee SK (2014) Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: Chart analysis and practice recommendations. *Int J Clin Pharmacol Ther* **52**:1017–1022.
- Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, Dirstine J, Avorn J, and Asch SM (2006) The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. *Arch Intern Med* **166**:332–337.
- Soryal I and Richens A (1992) Bioavailability and dissolution of proprietary and generic formulations of phenytoin. *Neurol Neurosurg Psychiatry* **55**:688–691.
- Sperling MR (2004) The consequences of uncontrolled epilepsy. *CNS Spectrums* **9**:98–109.
- Tamargo J, Le Heuzey JY, and Mabo P (2015) Narrow therapeutic index drugs: A clinical pharmacological consideration to flecainide. *Eur J Clin Pharmacol* **71**:549–567.
- Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, and Polli JE. (2015) Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. *Epilepsia* **56**: 1415–1424.
- Vergely N, Mounier C, Guy C, Millot L, and Estour B (2002) Generic carbamazepine-induced subacute adrenal insufficiency? *Ann Med Interne (Paris)* **153**:481–482.
- Vossler DG, Anderson GD, and Bainbridge J (2016) AES Position Statement on Generic Substitution of Antiepileptic Drugs. *Epilepsy Curr* **16**:209–211.
- Welty TE, Pickering PR, Hale BC, and Arazi R (1992) Loss of seizure control associated with generic substitution of carbamazepine. *Ann Pharmacother* **26**:775–777.
- Wilner AN (2004) Therapeutic equivalency of generic antiepileptic drugs: Results of a survey. *Epilepsy Behav* **5**:995–998.
- Yamada M and Welty TE (2011) Generic substitution of antiepileptic drugs: A systematic review of prospective and retrospective studies. *Ann Pharmacother* **45**:1406–1415.

FOOTNOTES

Dr. Reddy research work was supported by National Institutes of Health grants [Grant NS052158, NS051398]; CounterACT Program, National Institutes of Health, Office of the Director and the National Institute of Neurologic Disorders and Stroke [Grant R21-NS076426, U01-NS083460, R21-NS099009, U01-NS117209, U01-NS117278]; and Texas A&M Presidential X-Grant. Reddy work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the FY 2015 Epilepsy Research Program under Award #W81XWH-16-1-0660. Sarah Elmer received a summer research stipend from the Texas A&M University College of Medicine. *Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the U.S. Department of Defense or the National Institutes of Health. No author has an actual or perceived conflict of interest with the contents of this article.*

FIGURE CAPTIONS

Figure 1. Introduction of generic antiseizure medications (ASMs) by year. First generation ASMs were introduced prior to 1965, while second generation ASMs are structurally different from barbiturate type agents. Third generation ASMs are developed mostly based on target mechanism or seizure indication. Adapted with permission from Löscher and Klein (2020).

Table 1. Common generic ASMs Prescribed in the U.S.

Broad-Spectrum ASMs	Name of Drug^{a,b,c}
	Clobazam (Onfi)
	Clonazepam (Klonopin)
	Diazepam (Valium)
	Lamotrigine (Lamictal)
	Levetiracetam (Keppra)
	Rufinamide (Banzel)
	Topiramate (Topamax)
	Valproic Acid (Depakene)
	Zonisamide (Zonegran)
Narrow-Spectrum ASMs	Carbamazepine (Tegretol)
	Ethosuximide (Zarontin)
	Ezogabine (Trobalt)
	Gabapentin (Neurontin)
	Lacosamide (Vimpat)
	Oxcarbazepine (Trileptal)
	Perampanel (Fycompa)
	Phenobarbital (Luminal)
	Phenytoin (Dilantin)
	Pregabalin (Lyrica)
	Vigabatrin (Sabril)

^a Reddy, 2020

^b Brodie et al., 2016

^c Lewis, 1978

Table 2. Molecular classification of ASMs

Mechanism^a	Drug^a
Blockage of voltage-gated sodium channels	Phenytoin
<i>-Block firing propagation</i> <i>-Stabilize neuronal membranes</i> <i>-Reduce neurotransmitter release</i> <i>-Reduce focal firing</i> <i>-Reduce seizure spread</i>	Fosphenytoin
	Carbamazepine
	Valproate
	Lamotrigine
	Oxcarbazepine
	Esclicarbazepine
	Lacosamide
Enhancement of GABA inhibition	Phenobarbital
<i>-Increase neuronal hyperpolarization</i> <i>-Increase seizure threshold</i> <i>-Reduce firing rate</i>	Primidone
	Diazepam
	Lorazepam
	Clonazepam
	Tiagabine
	Valproate
	Vigabatrin
Blockage of low-threshold (T-type) Ca²⁺ channels	Ethosuximide
<i>-Reduce neurotransmitter release— slow depolarization</i>	Gabapentin
	Valproate
Reduction of glutamate excitation	Felbamate
<i>-Reduce excitatory transmission</i> <i>-Reduce focal firing</i>	Gabapentin
	Parampanel
Binding to SV2 synaptic vesicle protein	Levetiracetam
<i>-Reduce transmitter release</i>	Brivacetam
α2δ Ligands	Gabapentin
	Pregabalin
Modulators of K⁺ (KCNQ2-5) channels	Ezogabine (retigabine)
<i>-Reduce bursts of firing</i> <i>-Hyperpolarize neurons</i>	

^a Reddy, 2020

Table 3. Top 13 Most Commonly Prescribed Generic ASMs in the U.S. in 2018

Brand and Generic Name	Year of First Generic Approval^a	Ranking^b
Gabapentin (Neurontin)	2003	#1 for Generic ASMs #13 Overall
Clonazepam (Klonopin)	1996	#2 for Generic ASMs #38 Overall
Lorazepam (Ativan)	1985	#3 for Generic ASMs #55 Overall
Lamotrigine (Lamictal)	2006	#4 for Generic ASMs #70 Overall
Topiramate (Topamax)	2003	#5 for Generic ASMs #77 Overall
Pregabalin (Lyrica)	2019	#6 for Generic ASMs #79 Overall
Diazepam (Valium)	1985	#7 for Generic ASMs #91 Overall
Levetiracetam (Keppra)	2008	#8 for Generic ASMs #118 Overall
Valproic Acid (Depakote)	1986	#9 for Generic ASMs #120 Overall
Phenytoin (Dilantin)	1992	#10 for Generic ASMs #158 Overall
Oxcarbazepine (Trileptal)	2007	#11 for Generic ASMs #176 Overall
Carbamazepine (Tegretol)	1986	N/A for Generic ASMs N/A Overall
Ethosuximide (Zarontin)	1993	N/A for Generic ASMs N/A Overall

^a FDA Approved Drug Products, 2021

^b Fuentes et al., 2018

Table 4. ASMs that do and do not induce hepatic enzymes

Enzyme-Inducing ASMs^a	Enzyme non-inducing ASMs^a
Brivaracetam (Briviact)**	
Carbamazepine (Tegretol)	Clonazepam (Rivotril)
Clobazam (Onfi)	Ethosuximide (Zarontin)
Esclicarbazepine (Aptiom)	Ezogabine
Felbamate (Felbatol)	Gabapentin (Neurontin)
Lamotrigine (Lamictal)*	Lacosamide
Oxcarbazepine (Trileptal)	Levetiracetam (Keppra)
Perampanel (Fycompa)**	Stiripentol
Phenobarbital (Luminal)	Pregabalin (Lyrica)
Phenytoin (Dilantin)	Tiagabine (Gabitril)
Primidone (Mysoline)	Vigabatrin (Sabril)
Rufinamide (Banzel)	Valproate (Depakote)
Topirimate (Topamax)	Zonisamide (Zonegran)

**weak enzyme inducer; **weak enzyme inhibitor*

^a Reddy, 2020

Table 5. Commonly Prescribed Generic ASMs and their Accepted Therapeutic Ranges

Generic ASM^a	Ranking Among Generic ASMs^b	Therapeutic Range	FDA Bioequivalence-extrapolated Therapeutic Range*	NTI Classification?
Gabapentin	1	4-20 µg/ml	3.2–25 µg/ml	No
Lamotrigine	4	4-20 µg/ml	3.2–25 µg/ml	No
Topiramate	5	10-20 µg/ml	8–25 µg/ml	No
Levetiracetam	8	5-40 µg/ml	4–50 µg/ml	No
Valproic acid	9	50-100 µg/ml	40–125 µg/ml	Yes
Phenytoin	10	10-20 µg/ml	8–25 µg/ml	Yes
Carbamazepine	N/A	4–12 µg/ml	3.2–15 µg/ml	Yes
Ethosuximide	N/A	40-100 µg/ml	32–125 µg/ml	Yes
Phenobarbital	N/A	20-40 µg/ml	16-50 µg/ml	Yes

**based on FDA criteria (80% to 125%) for peak concentration, C_{max}*

^a Atif et al., 2016

^b Fuentes et al., 2018

Figure-1